ABBV-744

BD2 domain selective BET inhibitor

orally efficacious in XG w/o platelet, GI tox

from SBDD of BD1/2 dual inhibitors

Nature, 2020, 578, 306-310

AbbVie, North Chicago, IL

ABBV-744 (AbbVie oral in vivo BD2 domain selective BET inhibitor)


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.